<DOC>
	<DOCNO>NCT00523432</DOCNO>
	<brief_summary>The aim trial determine recommend phase II dose weekly intravenous topotecan combination fix dose ( 25 mg 15 mg ) weekly intravenous temsirolimus patient without prior pelvic radiation .</brief_summary>
	<brief_title>A Phase I Study CCI-779 ( Temsirolimus ) Combination With Topotecan Patients With Gynecologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Histologically confirm recurrent metastatic ovarian carcinoma , fallopian tube carcinoma , primary peritoneal carcinoma , cervical carcinoma , endometrial carcinoma , vulvar carcinoma , vaginal carcinoma , carcinosarcoma ovary , endometrium cervix . Prior Therapy : least one may three prior cytotoxic chemotherapeutic regimen management primary disease . Must least 18 year age . GOG performance status must 0 1 . Patients must adequate organ marrow function define : hemoglobin ≥10g/dL absolute neutrophil count ≥1,500/uL platelets ≥100,000/uL total bilirubin institutional upper limit normal AST ( SGOT ) /ALT ( SGPT ) institutional upper limit normal creatinine institutional upper limit normal cholesterol ≤ 350 mg/dL ( fast ) triglyceride ≤ 400 mg/dL ( fast ) albumin ≥ 3.0 mg/dL negative pregnancy test woman able child Ability understand willingness sign write informed consent document . Prior therapy topotecan More 3 prior cytotoxic chemotherapeutic regimen treatment temsirolimus mTOR inhibitor Concomitant hormonal therapy radiation therapy Clinically significant infection medical problem significant severity History unstable angina myocardial infarction within past six month Known brain metastasis unless metastasis control prior surgery radiotherapy , patient neurologically stable steroid least 4 week . Any requirement oxygen Can receive potent enzymeinducing antiepileptic drug ( EIAEDs ; e.g. , phenytoin , carbamazepine , phenobarbital ) potent CYP3A4 inducer rifampin St. John 's wort , may decrease temsirolimus level . Use agent potently inhibit CYP3A4 ( hence may raise temsirolimus level ) , ketoconazole , discourage , specifically prohibit .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>uterine cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>endometrial cancer</keyword>
	<keyword>vaginal cancer</keyword>
	<keyword>peritoneal cancer</keyword>
	<keyword>reproductive cancer</keyword>
</DOC>